Atraumatic bilateral femur fracture in long-term bisphosphonate use

Orthopedics

Volumn 32, Issue 8, 2009, Pages 607-

  Goddard, Maria S ^a   Reid, Kristoff R ^a   Johnston, James C ^a   Khanuja, Harpal S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ANAMNESIS; ARTICLE; BONE REMODELING; BONE TURNOVER; CASE REPORT; FEMALE; FEMUR FRACTURE; FOLLOW UP; HIP RADIOGRAPHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTRAMEDULLARY NAILING; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; LONGITUDINAL STUDY; MALE; MULTIPLE TRAUMA; OSTEOPOROSIS; OSTEOSYNTHESIS; REVIEW;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; FRACTURE FIXATION, INTERNAL; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIPLE TRAUMA; OSTEOPOROSIS;

EID: 70349209123     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20090624-27     Document Type: Article

References (19)

1. Cheung RKH, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007; 13(6):485-489.
2. Goh SK, Yang KY, Koh JSB, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. A caution. J Bone Joint Surg Br. 2007; 89(3):349-353. (Pubitemid 46563912)
3. Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008; 39(2):224-231.
4. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-1306.
5. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-350. (Pubitemid 351630250)
6. Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report. Acta Orthop. 2008; 79(4):565-567.
7. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006; 61(1):31-33.
8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90(3):1294-1301. (Pubitemid 40463979)
9. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008; 93(8):2948-2952.
10. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24):2927-2938.
11. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997; 12(10):1700-1707. (Pubitemid 27422371)
12. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004; 19(8):1259-1269. (Pubitemid 41094366)
13. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004; 20(8):1291-1300. (Pubitemid 39120794)
14. Yang KH, Won JH, Yoon HK, Ryu JH, Choo KS, Kim JS. High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. Yonsei Med J. 2007; 48(4):653-658.
15. Ott SM. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005; 90(3):1897-1899.
16. Sebba A. Osteoporosis: how long should we treat? Curr Opin Endocrinol Diabetes Obes. 2008; 15(6):502-507.
17. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000; 85(2):720-726.
18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-1541.
19. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-1199. (Pubitemid 38339363)